Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study.
BACKGROUND
Clinical trials have demonstrated that pharmacotherapies can safely treat attention-deficit/hyperactivity disorder (ADHD) in adulthood. Eligibility criteria in these trials may significantly limit their external validity by excluding a significant portion of adults with ADHD in the general population. In particular, exclusion criteria may frequently exclude individuals with comorbid mental health conditions, which are common in the adult ADHD population.


METHODS
We addressed the representativeness of clinical trials by comparing 146 adult clinical trial participants with DSM-IV ADHD and a community sample composed of 124 adults with DSM-IV ADHD and 123 non-ADHD controls. Subjects were compared on socioeconomic status, Hollingshead occupational code, cognitive measures, lifetime psychopathology, and Global Assessment of Functioning (GAF) scale ratings.


RESULTS
Adults with ADHD in the community sample had higher rates of lifetime psychiatric comorbidity, lower GAF scores, and lower occupational codes than those in the clinical trial. The clinical trial eligibility criteria would have excluded 61% of community sample adults with ADHD. This excluded portion of the community sample had higher rates of lifetime psychiatric comorbidity and lower GAF scores than clinical trial participants.


CONCLUSIONS
Adults with ADHD participating in the clinical trial had less evidence of functional impairment and endorsed less psychiatric comorbidity than the majority of community sample subjects with ADHD. This suggests that findings from clinical trials may have limited external validity for adults with ADHD in the general population, particularly for those adults with ADHD with the greatest burden of comorbid psychopathology.
Surman
Craig B H
CB
Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Ste 2000, 185 Alewife Brook Pkwy, Cambridge, MA 02138, USA. csurman@partners.org
Monuteaux
Michael C
MC
Petty
Carter R
CR
Faraone
Stephen V
SV
Spencer
Thomas J
TJ
Chu
Nicole F
NF
Biederman
Joseph
J
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy; D002986:Clinical Trials as Topic / Q000592:standards* / Q000706:statistics & numerical data; D003071:Cognition; D015897:Comorbidity; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D019370:Observation / Q000379:methods; D009790:Occupations / Q000706:statistics & numerical data; D018579:Patient Selection; D011569:Psychiatric Status Rating Scales; D012111:Residence Characteristics / Q000706:statistics & numerical data; D012494:Sampling Studies; D015983:Selection Bias; D012720:Severity of Illness Index; D012923:Social Class; D014481:United States
Psychiatry Res. 1994 Jul;53(1):13-29
7991729
Arch Gen Psychiatry. 1993 Jul;50(7):565-76
8317950
Am J Psychiatry. 2005 Sep;162(9):1621-7
16135620
Compr Psychiatry. 1996 Nov-Dec;37(6):393-401
8932963
Biol Psychiatry. 2004 Apr 1;55(7):692-700
15038997
Am J Psychiatry. 2006 Oct;163(10):1720-9; quiz 1859
17012682
Arch Gen Psychiatry. 1982 Oct;39(10):1157-67
7125846
Arch Gen Psychiatry. 1982 Aug;39(8):879-83
7103676
Biol Psychiatry. 2005 Mar 1;57(5):456-63
15737659
Am J Psychiatry. 2006 Apr;163(4):716-23
16585449
Am J Psychiatry. 1993 Dec;150(12):1792-8
8238632